StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note released on Tuesday morning. The brokerage issued a sell rating on the stock.
Separately, Maxim Group cut shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th.
Check Out Our Latest Report on Moleculin Biotech
Moleculin Biotech Stock Performance
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Articles
- Five stocks we like better than Moleculin Biotech
- Investing in Construction Stocks
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- Where Do I Find 52-Week Highs and Lows?
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Short Selling: How to Short a Stock
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
